Cargando…

Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation

Androgen deprivation therapy is the cornerstone treatment of advanced prostate cancer. Eventually prostate cancer cells overcome androgen deprivation therapy, giving rise to castration resistant prostate cancer (CRPC) characterized by increased androgen receptor (AR) activity. Understanding the cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nätkin, Reetta, Pennanen, Pasi, Syvälä, Heimo, Bläuer, Merja, Kesseli, Juha, Tammela, Teuvo L. J., Nykter, Matti, Murtola, Teemu J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942993/ https://www.ncbi.nlm.nih.gov/pubmed/36809527 http://dx.doi.org/10.1371/journal.pone.0281645

Ejemplares similares

The Importance of LDL and Cholesterol Metabolism for Prostate Epithelial Cell Growth
por: Murtola, Teemu J., et al.
Publicado: (2012)

Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial
por: Raittinen, Paavo V.H., et al.
Publicado: (2021)

Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases
por: Sattari, Mina, et al.
Publicado: (2023)

Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer
por: Raittinen, Paavo, et al.
Publicado: (2020)

Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor’s Immune Environment
por: Siltari, Aino, et al.
Publicado: (2022)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen
por: Kukkonen, Konsta, et al.
Publicado: (2022)

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kaapu, Kalle J, et al.
Publicado: (2016)

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kinnunen, Pete T. T., et al.
Publicado: (2017)

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial
por: Veitonmäki, Thea, et al.
Publicado: (2016)

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men
por: Siltari, Aino, et al.
Publicado: (2020)

Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol
por: Siltari, Aino, et al.
Publicado: (2022)

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
por: Murtola, Teemu J., et al.
Publicado: (2018)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study
por: Peltomaa, A. I., et al.
Publicado: (2021)

Transcription Factors Involved in Prostate Gland Adaptation to Androgen Deprivation
por: Rosa-Ribeiro, Rafaela, et al.
Publicado: (2014)

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
por: Taavitsainen, S., et al.
Publicado: (2021)

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
por: Ferrari, Nicoletta, et al.
Publicado: (2017)

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer
por: Salminen, Jukka K., et al.
Publicado: (2022)

Balance between Noise and Information Flow Maximizes Set Complexity of Network Dynamics
por: Mäki-Marttunen, Tuomo, et al.
Publicado: (2013)

Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer
por: Sjöblom, Liisa, et al.
Publicado: (2016)

Improved renal cancer prognosis among users of drugs targeting renin-angiotensin system
por: Eskelinen, Tommi, et al.
Publicado: (2021)

Does Androgen Deprivation for Prostate Cancer Affect Normal Adaptation to Resistance Exercise?
por: Nilsen, Tormod S., et al.
Publicado: (2022)

Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine
por: Jasu, Juho, et al.
Publicado: (2021)

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level
por: Peltomaa, Antti I., et al.
Publicado: (2022)

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
por: Kallio, Heini M. L., et al.
Publicado: (2018)

Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer
por: Rantapero, Tommi, et al.
Publicado: (2020)

Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time
por: Pylväläinen, Juho, et al.
Publicado: (2019)

Epigenetically altered miR-193b targets cyclin D1 in prostate cancer
por: Kaukoniemi, Kirsi M, et al.
Publicado: (2015)

Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men
por: Kaapu, Kalle J., et al.
Publicado: (2018)

Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy
por: Filon, Mikolaj J., et al.
Publicado: (2022)

Engineering osteoblastic metastases to delineate the adaptive response of androgen-deprived prostate cancer in the bone metastatic microenvironment
por: Bock, Nathalie, et al.
Publicado: (2019)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer
por: Zhang, Jingsong, et al.
Publicado: (2022)

RAS and PP2A activities converge on epigenetic gene regulation
por: Aakula, Anna, et al.
Publicado: (2023)

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine
por: Nurminen, Anssi, et al.
Publicado: (2023)

Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression
por: Latonen, Leena, et al.
Publicado: (2018)

Overall and worst gleason scores are equally good predictors of prostate cancer progression
por: Tolonen, Teemu T, et al.
Publicado: (2011)

DOT1L-HES6 fusion drives androgen independent growth in prostate cancer
por: Annala, Matti, et al.
Publicado: (2014)

Information-Theoretic Analysis of the Dynamics of an Executable Biological Model
por: Sadot, Avital, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5f4ov8i5p5cec91miul7k848v3